Research programme: casein kinase I alpha stimulants - StemSynergy Therapeutics

Drug Profile

Research programme: casein kinase I alpha stimulants - StemSynergy Therapeutics

Alternative Names: SSTC-104; SSTC3

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator StemSynergy Therapeutics
  • Class Small molecules
  • Mechanism of Action Casein kinase Ialpha stimulants; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer
  • No development reported Synovial sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Synovial-sarcoma in USA
  • 17 Jul 2017 Preclinical trials in Colorectal cancer in USA, before July 2017
  • 14 Jul 2017 StemSynergy Therapeutics plans a phase I trial for Colorectal cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top